RxDoctor Payments Data

Saleha Ahmed, MD

Family Medicine · Houston, TXNPI 1710917380

Payments from drug & device makers

$4,298in general payments, 2019–2025

Across 256 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$668
  • Lilly USA, LLC$587
  • GSK$578
  • Amgen$474
  • Radius Health, Inc.$341
  • Bayer$309
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$4,277100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,298 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$187,432
Medicare patients
114
Services billed
3,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol204$209,825
OzempicSemaglutide113$136,100
ProliaDenosumab77$132,410
JardianceEmpagliflozin127$123,243
MounjaroTirzepatide84$101,893
Evenity (2 Syringes)Romosozumab-Aqqg30$89,370
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$66,860
Breztri AerosphereBudesonide/Glycopyr/Formoterol68$51,073
XareltoRivaroxaban41$42,667
EliquisApixaban20$28,520
LinzessLinaclotide30$19,454
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$16,675
Repatha SureclickEvolocumab15$16,063
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$8,590
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$7,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$668$260,898272 claims
AmgenProlia, Evenity (2 Syringes)$474$221,780107 claims
Novo NordiskOzempic$60$136,100113 claims
Boehringer IngelheimJardiance, Combivent Respimat$53$130,417139 claims
Lilly USA, LLCMounjaro$587$101,89384 claims
GSKTrelegy Ellipta$578$66,86084 claims
Johnson & JohnsonXarelto$183$42,66741 claims
PfizerEliquis$27$28,52020 claims
AbbVieLinzess$62$19,45430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →